MULTIPLE MYELOMA

This study tested whether a combination of two drugs, pomalidomide and dexamethasone, could help control a hard-to-treat form of blood cancer called multiple myeloma. It focused on 63 patients whose cancer had specific genetic features linked to poorer outcomes and had come back …

This study tested whether a multiple myeloma drug called isatuximab could be given as a simple injection under the skin instead of through an IV. Researchers compared both methods in 56 patients whose cancer had returned or stopped responding to previous treatments. The main goal…

This study tested an intensive treatment approach for primary plasma cell leukemia, a rare and aggressive form of blood cancer with very poor survival rates. Forty patients under age 70 received strong chemotherapy followed by stem cell transplants, with some receiving two transp…

This study tested a personalized cell therapy for adults with multiple myeloma, a blood cancer. It was for patients whose cancer did not respond well enough to a prior stem cell transplant and standard maintenance drug. Doctors collected and re-engineered the patients' own immune…

This study tested a new type of stem cell transplant for people with high-risk multiple myeloma, a serious blood cancer. Doctors used specially treated umbilical cord blood cells for the transplant, hoping it would be safer and more effective than standard transplants. The main g…

This small, early-stage study tested a new type of personalized immune therapy called C-CAR088 in patients whose multiple myeloma had returned or stopped responding to standard treatments. Doctors collected and genetically modified each patient's own T-cells to target a protein (…

This completed Phase 2 trial tested a combination of four medications (elotuzumab, carfilzomib, lenalidomide, and dexamethasone) as the first treatment for 46 adults newly diagnosed with multiple myeloma, a cancer of plasma cells. The main goal was to see how many patients achiev…

This study tested a new way of giving the drug elranatamab to people with multiple myeloma that has come back or stopped responding to other treatments. The goal was to see if starting with lower 'step-up' doses and then giving the drug less often could make it safer and more eff…

This study tested if giving a key drug (isatuximab) as a simple injection under the skin works as well as giving it through an IV drip for people newly diagnosed with multiple myeloma. Over 500 patients eligible for a stem cell transplant received standard therapy plus the drug i…

This large, completed Phase 3 study tested whether adding a targeted drug (daratumumab) to a standard two-drug therapy (lenalidomide and dexamethasone) was better at controlling newly diagnosed multiple myeloma. It involved 737 older adults or those ineligible for intensive stem …

This study aimed to find the best way to use the drug pomalidomide for patients whose multiple myeloma has returned or stopped responding to treatment. It compared two approaches: a stem cell transplant followed by the drug, versus staying on a three-drug combination. The goal wa…

This study tested whether the drug denosumab is safe and effective for protecting bones in people with multiple myeloma who also have severe kidney damage. It involved 55 participants who could not take standard bone-protecting drugs due to their kidney condition. Researchers mea…

This study tested whether adding a newer drug called ixazomib to a standard two-drug combination could better control multiple myeloma in patients whose cancer had returned or stopped responding to several prior treatments. It involved 112 adults and compared the three-drug combi…

This study tested a new combination of four drugs for people whose multiple myeloma had returned or stopped responding to one prior treatment. The goal was to see if this four-drug mix could reduce the amount of cancer in the body. After an initial intensive treatment phase, pati…

This early-stage study tested a new approach for hard-to-treat cancers that had spread or didn't respond to standard treatments. Researchers collected a patient's own natural killer (NK) immune cells, grew more of them in a lab, and then gave them back after using a drug (bortezo…

This study tested a two-step stem cell transplant method for patients with high-risk blood cancers like leukemia and lymphoma. It used a drug called cyclophosphamide before the transplant to help prevent a dangerous complication called graft-versus-host disease. The goal was to i…

This early-stage trial tested a new oral drug, VS-6766, given alone and later combined with another drug called everolimus. The main goal was to find safe and tolerable dosing schedules for patients with advanced solid tumors or multiple myeloma that had stopped responding to sta…

This study tested if a drug called palifermin, given before a stem cell transplant, could make the procedure safer and more effective. It involved 34 adults with blood cancers who received stem cells from an unrelated, matched donor. The main goals were to find a safe dose and se…

This study tested the safety of adding a new drug called daratumumab to two existing medications (lenalidomide and dexamethasone) for people with multiple myeloma that had returned after previous treatments. The trial involved 45 participants and aimed to find the safest and most…

This study tested a combination of three cancer drugs (lenalidomide, bortezomib, and dexamethasone) in 46 adults newly diagnosed with multiple myeloma, a cancer of plasma cells. The main goals were to see how well the treatment worked to control the cancer and to check if giving …

This study tested a new combination of two drugs, acalabrutinib and ACP-319, for people with B-cell cancers like non-Hodgkin's lymphoma and multiple myeloma. The main goals were to find the safest dose and see if the treatment was effective at controlling the disease. It involved…

This study tested a combination of three drugs (pomalidomide, cyclophosphamide, and dexamethasone) in 100 adults with multiple myeloma whose cancer had returned after their first treatment. The goal was to see if this new drug combination could effectively control the disease in …

This study tested whether adding a drug called carfilzomib to two existing medications (pomalidomide and dexamethasone) could help control multiple myeloma in patients whose cancer had returned or stopped responding to previous treatments. The trial involved 25 adults who had alr…

This early-stage trial tested a new drug called cevostamab in 355 patients whose multiple myeloma had returned or stopped responding to other treatments. The main goal was to find safe dosage levels and understand how the drug moves through the body. Researchers monitored side ef…

This study tested the safety and early effectiveness of combining two immunotherapy drugs, nivolumab and daratumumab, for people with multiple myeloma that has returned or stopped responding to standard treatments. It involved about 320 participants with various blood cancers, fo…

This study tested an experimental drug called belantamab mafodotin in people with advanced multiple myeloma, a blood cancer, who had already tried and stopped responding to at least three other types of treatment. The main goal was to see if the drug could shrink the cancer and f…

This study compared two drug combinations used to collect a patient's own stem cells from their blood before a transplant for multiple myeloma. Researchers wanted to see if one method (using etoposide) was more effective and caused fewer side effects than the standard method (usi…

This pilot study tested a combined transplant from a partially matched family donor. It aimed to treat patients who had both a serious blood disorder (like leukemia) and advanced kidney disease at the same time. The goal was to cure the blood disorder and restore kidney function …

This study tested a combination of three medications (ixazomib, cyclophosphamide, and dexamethasone) as the first treatment for adults with multiple myeloma, a type of blood cancer. The goal was to see if this combination could control the disease effectively while causing fewer …

This early-stage study aimed to find a safe dose for a new three-drug combination (ibrutinib, lenalidomide, and dexamethasone) for adults with multiple myeloma that has returned or stopped responding to prior treatments. The main goal was to check for serious side effects and det…

This early-stage study tested a new, lab-made cell therapy called FT576 in patients with multiple myeloma that had returned or stopped responding to standard treatments. The main goals were to find a safe dose and see if the treatment, given alone or with an existing drug (daratu…

This study tested whether adding a drug called daratumumab to a standard two-drug treatment (pomalidomide and dexamethasone) works better for people with multiple myeloma that has come back or stopped responding to prior treatments. It involved 304 adults whose cancer had progres…

This early-stage study tested the safety and initial effectiveness of combining two drugs, acalabrutinib and pembrolizumab, for people with various blood cancers. It involved 161 participants with conditions like lymphoma and leukemia. The main goal was to see if the combination …

This study tested a new drug called Elranatamab for Chinese patients with a severe form of multiple myeloma that no longer responds to standard treatments. The drug is an injection that works by activating the body's own immune system to attack the cancer cells. The trial had two…

This study tested a new weekly dosing schedule of a drug called carfilzomib, combined with standard medications, for older adults newly diagnosed with multiple myeloma. The main goals were to find the safest, most effective dose and to see how well the treatment controlled the ca…

This study tested whether adding the medication bortezomib to the second of two stem cell transplants helps people with multiple myeloma stay in remission longer. It involved 148 adults who received a first transplant with the standard drug melphalan, followed by a second transpl…

This early-stage study tested whether adding very high doses of vitamin C (ascorbic acid) to a low dose of chemotherapy (melphalan) is safe and might help control advanced multiple myeloma. It involved 6 patients whose cancer had returned or stopped responding to multiple prior t…

This large, completed study aimed to find the most effective treatment strategy for adults newly diagnosed with multiple myeloma, a blood cancer. It compared two main approaches: one using a combination of drugs alone, and another that adds a stem cell transplant followed by addi…

This study tested two drug combinations to help collect stem cells from patients with multiple myeloma. The goal was to see if these combinations could safely and effectively gather enough stem cells for the patient's own transplant. About 30 patients were randomly assigned to re…

This early-stage study tested an experimental drug called CC-95266 in 130 adults with multiple myeloma that had returned or stopped responding to previous treatments. The main goal was to find the safest dose and check for side effects, while also looking for early signs that the…

This study tested the safety of an experimental drug called talquetamab in 15 Japanese patients with multiple myeloma that had returned or stopped responding to standard treatments. The main goal was to see how well patients tolerated the drug at a specific dose level. Researcher…

This study tested an experimental cell therapy called bb2121 in adults with multiple myeloma, a cancer of plasma cells. It focused on people whose cancer had come back after several treatments or who were at high risk of early relapse. The therapy involves collecting and genetica…

This study tested a new, potentially safer drug combination to prepare patients for a half-matched bone marrow transplant. It involved 43 adults with blood cancers like multiple myeloma who could not tolerate standard high-dose treatments. The goal was to see if this gentler prep…

This study tested whether combining three drugs (carfilzomib, lenalidomide, and dexamethasone) is safe and effective for people newly diagnosed with multiple myeloma, a cancer of plasma cells in the bone marrow. Researchers worked with 29 participants to find the highest dose pat…

This small pilot study tested whether providing plant-based meals could help multiple myeloma patients during a stem cell transplant. Researchers delivered meals and snacks to 26 patients to see if improving diet could support their gut health and recovery. The main goal was to c…

This study tested whether starting treatment early could prevent a pre-cancerous blood condition called smoldering multiple myeloma from turning into active cancer. It enrolled 55 adults at high risk of progression and gave them a combination of three drugs (carfilzomib, lenalido…

This study tested whether fasting for 14 hours overnight could help prevent blood cancer in overweight people with early-stage blood cell conditions. 23 participants were randomly assigned to either follow the fasting schedule or receive general healthy lifestyle advice for 4 mon…

This pilot study tested a new support program designed to help rural-dwelling and Hispanic cancer survivors manage their chronic pain. The program connected 51 participants with a care team by phone or video to create personalized pain management plans. Researchers aimed to refin…

This study tested if a drug called colesevelam could safely reduce diarrhea caused by lenalidomide, a common maintenance therapy for multiple myeloma. It involved 25 adult patients with myeloma who were experiencing this specific side effect. The main goal was to see if their dia…

This study looked at whether starting supportive care services like counseling and therapy right after a multiple myeloma diagnosis leads to better quality of life compared to waiting six months. It involved 20 adult outpatients who were not eligible for a stem cell transplant. T…

This study tested whether cooling caps could prevent hair loss in people with multiple myeloma undergoing stem cell transplant. Researchers enrolled 31 patients to see if wearing special cold caps during chemotherapy could keep most hair intact. They also asked patients whether t…

This study tested whether distance Reiki therapy, delivered via video call, could improve quality of life and possibly affect the immune system in people with multiple myeloma. Thirty patients were divided into groups receiving real Reiki, fake (sham) Reiki, or no additional Reik…

This small pilot study tested whether a 6-session exercise and activity program could help people with multiple myeloma who struggle with daily tasks. The program aimed to improve physical function and quality of life by providing personalized exercises and encouraging meaningful…

This study looked at how autoimmune hemolytic anemia (AIHA), a rare type of anemia where the immune system attacks red blood cells, affects people with multiple myeloma, a type of blood cancer. Researchers followed 66 patients to see how common this anemia is in this group and wh…

This study measured how well people with multiple myeloma or Waldenstrom's macroglobulinemia respond to COVID-19 vaccines. Researchers tested 146 participants to see if their weakened immune systems could produce protective antibodies after vaccination. The goal was to understand…

This completed study aimed to see if certain blood measurements could help predict how newly diagnosed multiple myeloma patients might fare. Researchers followed 48 patients for one year after diagnosis, checking their blood thickness and protein ratios. The goal was to find conn…

This study aimed to see if new types of medical scans could better detect when early, pre-cancerous blood conditions progress to full multiple myeloma, a serious blood cancer. Researchers compared three different imaging techniques in 31 people diagnosed with either the early con…

This study aimed to understand why patients with the same type of blood cancer, like lymphoma or leukemia, can have very different outcomes. Researchers analyzed the genes in old tissue samples from 1,340 patients to see if they could find patterns that predict how the disease wi…

This study aimed to find better ways to spot early kidney injury in people newly diagnosed with multiple myeloma who are starting a specific treatment called daratumumab. Researchers collected blood and urine samples from 20 patients to measure certain proteins that might signal …

This study interviewed people with advanced multiple myeloma to learn about their treatment experiences and preferences. Researchers talked with 9 patients who had received at least five different treatment courses to understand what factors matter most when making treatment deci…

This study aimed to understand why farmers have higher rates of certain blood cancers. Researchers collected blood and urine samples from nearly 2,000 cancer-free male farmers over age 50 to look for early warning signs. They compared these signs to the farmers' pesticide use his…

This study aimed to understand how often patients with chronic lymphocytic leukemia or multiple myeloma experience financial difficulty due to their cancer treatment. Researchers surveyed 218 patients and their doctors to measure the financial burden, identify what types of costs…

This study aimed to understand if a protein in the blood called M-CSF could be a useful marker for bone damage in multiple myeloma. Researchers compared M-CSF levels in three groups: people with multiple myeloma, people with a related but non-cancerous condition (MGUS), and healt…

This study monitored the safety of Ninlaro (ixazomib) when used to treat multiple myeloma in real-world medical practice in China. Researchers followed 482 patients with multiple myeloma who were already taking or about to start Ninlaro treatment. The goal was to collect informat…